EMAIL THIS PAGE TO A FRIEND

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

[Study on effect of combination of Epimedii Folium and Ligustri Lucidi Fructus on osteoporosis rats induced by retinoic acid].


PMID 24791502

Abstract

To explore the effect of combination of Epimedii Folium and Ligustri Lucidi Fructus on osteoporosis rats induced by retinoic acid. Sixty three-month-old male Wistar rats were randomly divided into the normal control group, the model group, the Epimedii Folium group, the Ligustri Lucidi Fructus group, the combination group of Epimedii Folium and Ligustri Lucidi Fructus and the raloxifene group. The osteoporosis model was established through oral administration with retinoic acid for two weeks. Meanwhile, all of treatment groups were administered with corresponding drugs for three weeks. The contents of serum calcium (Ca), phosphorus (P), alkaline phosphatase (AKP) and tartrate-resistant acid phosphatase (StrACP) were detected, and the pathomorphological changes of femurs were observed. The model control group showed much lower contents of serum Ca and P than the normal control group, but with significantly higher AKP and StrACP activity than the normal control group. The femoral head area showed reduced, narrow and sparse trabecular bones, with typical osteoporosis-like changes. Compared with the model control group, all of treated groups showed significant increase in Ca and P contents in serum, and down-regulate AKP and StrACP levels, while trabecular bones became more and wider, and densely interweaved as a reticular formation. Among them, the combination group showed the most significant effect. Epimedii Folium and Ligustri Lucidi Fructus could effectively correct the abnormal bone metabolism and improve pathological conditions of bone tissues, so as to show the anti-osteoporosis effect. The combined application of the two drugs showed a better efficacy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

P1146 Phosphatase, Acid from potato, lyophilized powder, ≥3.0 units/mg solid
P3752 Phosphatase, Acid from potato, lyophilized powder, ≥0.5 unit/mg solid
P1435 Phosphatase, Acid from sweet potato, ammonium sulfate suspension, ≥10.0 units/mg protein (modified Warburg-Christian)
P3627 Phosphatase, Acid from wheat germ, ≥0.4 unit/mg solid
P8361 Phosphatase, Alkaline bovine, recombinant, expressed in Pichia pastoris, ≥4000 units/mg protein
P0114
Phosphatase, Alkaline from bovine intestinal mucosa, BioUltra, buffered aqueous glycerol solution, ≥6,000 DEA units/mg protein
A2356
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous glycerol solution, ≥5,500 DEA units/mg protein
P7923
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous glycerol solution, ≥4,000 DEA units/mg protein
P6774
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous solution, ≥2,000 DEA units/mg protein
P5521
Phosphatase, Alkaline from bovine intestinal mucosa, ≥2,000 DEA units/mg protein
P7640
Phosphatase, Alkaline from bovine intestinal mucosa, lyophilized powder, ≥10 DEA units/mg solid
P4978 Phosphatase, Alkaline from calf intestine, buffered aqueous glycerol solution
P4252 Phosphatase, Alkaline from Escherichia coli, ammonium sulfate suspension, 30-90 units/mg protein (modified Warburg-Christian, in glycine buffer)
P4069 Phosphatase, Alkaline from Escherichia coli, buffered aqueous glycerol solution, 20-50 units/mg protein (in glycine buffer)
P5931 Phosphatase, Alkaline from Escherichia coli, lyophilized powder, 30-60 units/mg protein (in glycine buffer)
P3895 Phosphatase, Alkaline from human placenta, ≥10 units/mg solid (in glycine buffer)
P4439 Phosphatase, Alkaline from porcine kidney, lyophilized powder, ≥100 DEA units/mg protein
A2237 Phosphatase, Alkaline shrimp, ≥1,000 DEA units/mL, buffered aqueous glycerol solution, recombinant, expressed in proprietary host